Skip to main content

Advertisement

Table 3 Baseline scores and changes from baseline in efficacy outcome measures at weeks 24, 48 and 80 [Mean (SD)].

From: Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators

Measure Baseline Week 24 Week 48 Week 80
  N = 75 N = 73 N = 57 N = 45
UHDRS Motor Score 47.9 (15.9) -7.4 (9.8) * -5.6 (12.1) * -0.2 (11.0)
Total Chorea 14.9 (3.7) -5.8 (5.0) * -5.6 (5.5) * -4.6 (5.5) *
Gait 1.3 (0.6) -0.1 (0.6) 0.0 (0.7) 0.2 (0.7)
Parkinsonism 14.5 (5.7) -0.5 (2.7) 0.9 (4.1) 2.1 (4.3) *
Barnes Akathisia 0.2 (0.6) 0.1 (1.0) 0.1 (0.9) 0.0 (0.7)
Hamilton 4.1 (3.7) -0.0 (3.8) 0.7 (3.4) 0.4 (3.8)
Functional Checklist 18.1 (4.7) -0.3 (2.5) -1.1 (2.3) * -2.6 (3.3) *
Independence 75.7 (11.5) -2.4 (7.2) * -4.4 (6.0) * -7.0 (8.1) *
Behavioral Score (freq*severity) 6.7 (9.7) 3.4 (14.4) * 2.9 (9.3) * 3.5 (14.4)
Weight (kg) 72.4 (18.8) -1.2 (4.8) * -1.4 (7.4) -1.7 (6.5)
  N = 47 N = 45 N = 38 N = 30
Total Functional Capacity 7.6 (2.4) -0.5 (1.5) * -1.1 (1.4) * -2.0 (2.3) *
Verbal 17.2 (10.3) -2.0 (5.6) * -2.0 (5.8) * -3.6 (7.9) *
Symbol Digit 19.3 (11.2) -0.3 (5.5) -1.9 (4.7) * -4.8 (10.3) *
Stroop Color 42.6 (17.3) -4.4 (9.5) * -8.9 (11.4) * -11.0 (14.8) *
Stroop Words 49.8 (20.6) -1.2 (9.3) -7.9 (15.4) * -9.0 (17.4) *
Stroop Interference 23.2 (11.4) -2.7 (7.1) * -4.5 (7.0) * -5.0 (10.4) *
  1. * p < 0.05 (t-test)